Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2021-04-29
Target enrollment:
Participant gender:
Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in
delaying tumor progression in patients with metastatic renal cell cancer.